What are the current challenges in CRISPR-based Nanotherapeutics?
Despite the promising potential of CRISPR-based nanotherapeutics, several challenges need to be addressed:
Efficiency: Achieving high delivery efficiency to the target cells remains a significant challenge. Optimizing nanoparticle formulations and delivery methods is crucial for improving gene editing outcomes. Specificity: Ensuring the specificity of CRISPR-Cas9 targeting is essential to avoid off-target effects that could lead to unintended genetic modifications. Safety: Assessing the long-term safety and potential toxicity of nanoparticles is critical before clinical applications can be realized. Regulatory Hurdles: Navigating the regulatory landscape for the approval of CRISPR-based nanotherapeutics requires thorough evaluation of their efficacy and safety.
